Details of the Drug
General Information of Drug (ID: DMDAS5B)
| Drug Name |
Enalkiren
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
ENALKIREN; Enalquireno; 113082-98-7; Abbott-64662; Enalkirenum [INN-Latin]; Enalkirene [INN-French]; Enalquireno [INN-Spanish]; Abbott 64662; Enalkiren [USAN:INN]; UNII-0U7YZ42Z47; A-64662; CHEMBL300337; CHEBI:4787; 0U7YZ42Z47; A 64662; (alphaS)-alpha-((alphaS)-alpha-(3-Amino-3-methylbutyramido)-p-methoxyhydrocinnamamido)-N-((1S,2R,3S)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)imidazole-4-propionamide; Enalkirenum; Enalkirene
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 3 | Molecular Weight (mw) | 656.9 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 3.6 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 18 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 7 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 8 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
References


